UTX-TGR-205: A Phase 2b Randomized Study to Assess the Efficacy and Safety of the Combination of Ublituximab + TGR-1202 with or without Bendamustine and TGR-1202 alone in Patients with Previously Treated Non-Hodgkin’s Lymphoma.
This study is being done to see how effective the combination of investigational drugs, ublituximab and umbralisib (also referred to as TGR-1202), are when given together, compared to when TGR-1202 is given alone. After that part of the study is complete, investigators will want to see how effective the combination of investigational drugs ublitiximab and TGR-1202 is when given together compared to when the combination is given with bendamustine.
Principal Investigator
William W. MacLaughlin, MD
Contact
Ora Mae Jackson, RN, OCN
757-534-5565
[email protected]
Locations
Peninsula Cancer Institute
12100 Warwick Blvd. Suite 201
Newport News, VA 23601
Cancer Specialists of Tidewater
110-E Wimbledon Square
Chesapeake, VA 23320
Status
Recruiting
Category
Oncology
Study #